EUVIMEDOpdag EUVIMED
Open access · CC BY-NC-ND 4.0

Glucagon‐like peptide‐1 agonists combined with sodium‐glucose cotransporter‐2 inhibitors reduce weight in type 1 diabetes

Ebaa Al-Ozairi iD, Mohammad Irshad iD, Etab Taghadom, Litty Sojan, Jumana Al Kandari, Dherar Alroudhan, Carel W le Roux iD

Obesity · 2023

DOI: 10.1002/oby.23677 ↗

At a glance

Journal article in Obesity, 2023. Written by Ebaa Al-Ozairi and 6 co-authors. Institution: Dasman Diabetes Institute, Kuwait City, Kuwait. Major MEDLINE topics: Diabetes Mellitus, Type 2, Diabetes Mellitus, Type 1, Sodium-Glucose Transporter 2 Inhibitors. Cited 13 times so far (Crossref); 36 references. The full text is freely available (open access, CC BY-NC-ND 4.0).

AbstractSubjectsBibliografiske oplysningerCiteRelated studies

Abstract (original language)

Objective

This study evaluated whether adding sodium‐glucose cotransporter‐2 inhibitors (SGLT2i) and/or glucagon‐like peptide‐1 receptor agonists (GLP1‐RA) to insulin reduced weight and glycemia in people with type 1 diabetes.

Methods

This retrospective analysis of electronic health records evaluated 296 people with type 1 diabetes over 12 months after medications were first prescribed. Four groups were defined: control n = 80, SGLT2i n = 94, GLP1‐RA n = 82, and combination of drugs (Combo) n = 40. We measured changes at 1 year in weight and glycated hemoglobin (HbA1c).

Results

The control group did not have changes in weight or glycemic control. The mean (SD) percentage weight loss after 12 months was 4.4% (6.0%), 8.2% (8.5%), and 9.0% (8.4%) in the SGLT2i, GLP1‐RA, and Combo groups, respectively ( p < 0.001). The Combo group lost the most weight ( p < 0.001). The HbA1c reduction was 0.4% (0.7%), 0.3% (0.7%), and 0.6% (0.8%) in the SGLT2i, GLP1‐RA, and Combo groups, respectively ( p < 0.001). The Combo group had the biggest improvements in glycemic control and total and low‐density lipoprotein cholesterol compared with baseline (all p < 0.01). Severe adverse events were similar between all the groups, with no increased risk of diabetic ketoacidosis.

Conclusions

The SGLT2i and GLP1‐RA agents on their own improved body weight and glycemia, but combining the medications resulted in more weight loss. Treatment intensification appears to result in benefits with no difference in severe adverse events.

Subjects

MeSH terms (MEDLINE)

Diabetes Mellitus, Type 2Diabetes Mellitus, Type 1Sodium-Glucose Transporter 2 InhibitorsHumansHypoglycemic AgentsGlycated HemoglobinRetrospective StudiesGlucagon-Like Peptide 1Weight LossGlucoseSodiumGlucagon-Like Peptide-1 Receptor Agonists

Substances

Hypoglycemic AgentsSodium-Glucose Transporter 2 InhibitorsGlycated HemoglobinGlucagon-Like Peptide 1GlucoseSodiumGlucagon-Like Peptide-1 Receptor Agonists

Authors and institutions

  • Dasman Diabetes Institute, Kuwait City, Kuwait.
  • Department of Medicine, Faculty of Medicine, Kuwait University, Kuwait City, Kuwait.
  • Diabetes Complications Research Center, UCD Conway Institute, University College Dublin School of Medicine, Dublin, Ireland.
  • Diabetes Research Centre, Ulster University, Coleraine, UK.

ORCID profiles: Ebaa Al-Ozairi, Mohammad Irshad, Carel W le Roux

Cite

APA

Al-Ozairi, E., Irshad, M., Taghadom, E., Sojan, L., Al Kandari, J., Alroudhan, D., & le Roux, C. W. (2023). Glucagon‐like peptide‐1 agonists combined with sodium‐glucose cotransporter‐2 inhibitors reduce weight in type 1 diabetes. Obesity. https://doi.org/10.1002/oby.23677

Vancouver

Al-Ozairi E, Irshad M, Taghadom E, Sojan L, Al Kandari J, Alroudhan D, et al. Glucagon‐like peptide‐1 agonists combined with sodium‐glucose cotransporter‐2 inhibitors reduce weight in type 1 diabetes. Obesity. 2023. doi:10.1002/oby.23677

BibTeX
@article{AlOzairi2023,
  author = {Al-Ozairi, Ebaa and Irshad, Mohammad and Taghadom, Etab and Sojan, Litty and Al Kandari, Jumana and Alroudhan, Dherar and le Roux, Carel W},
  title = {Glucagon‐like peptide‐1 agonists combined with sodium‐glucose cotransporter‐2 inhibitors reduce weight in type 1 diabetes},
  journal = {Obesity},
  year = {2023},
  doi = {10.1002/oby.23677}
}
Start for free →